AMAG Pharmaceuticals (AMAG) Marked As A Dead Cat Bounce Stock
Trade-Ideas LLC identified
(
) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified AMAG Pharmaceuticals as such a stock due to the following factors:
- AMAG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $35.9 million.
- AMAG has traded 85,027 shares today.
- AMAG is up 3.1% today.
- AMAG was down 9.8% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMAG with the Ticky from Trade-Ideas. See the FREE profile for AMAG NOW at Trade-Ideas
More details on AMAG:
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. AMAG has a PE ratio of 4. Currently there are 5 analysts that rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.
The average volume for AMAG Pharmaceuticals has been 1.4 million shares per day over the past 30 days. AMAG has a market cap of $1.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.88 and a short float of 25.8% with 5.02 days to cover. Shares are down 38.5% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates AMAG Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and a generally disappointing performance in the stock itself.
Highlights from the ratings report include:
- AMAG's very impressive revenue growth greatly exceeded the industry average of 13.4%. Since the same quarter one year prior, revenues leaped by 277.1%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Even though the current debt-to-equity ratio is 1.09, it is still below the industry average, suggesting that this level of debt is acceptable within the Biotechnology industry. Despite the fact that AMAG's debt-to-equity ratio is mixed in its results, the company's quick ratio of 2.05 is high and demonstrates strong liquidity.
- The share price of AMAG PHARMACEUTICALS INC has not done very well: it is down 17.24% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1511.8% when compared to the same quarter one year ago, falling from $1.46 million to -$20.58 million.
- You can view the full AMAG Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.